INSULIN LISPRO MARKET ANALYSIS

Insulin Lispro MarketSize and Trends

Insulin lispro market has been significant due to the increasing prevalence of diabetes globally. The global insulin lispro market size is estimated to be valued at US$ 7.32 Bn in 2023, and is projected to reach US$ 11.15 Bn by 2030 at a CAGR of 6.2% from 2023 to 2030.

Insulin Lispro Market Trends:

• Increasing Adoption of Continuous Glucose Monitoring (CGM): Continuous glucose monitoring devices are becoming more widely used for diabetes management. CGM systems provide real-time glucose readings, helping individuals make informed decisions about insulin dosing. The integration of CGM with insulin pumps and smart devices creates a trend towards personalized insulin therapy and improved glycemic control. For instance, in February 2022, the U.S. Centers for Medicare & Medicaid Services (CMS) announced an expansion of Medicare coverage for all types of continuous glucose monitors (CGMs), including adjunctive and non-adjunctive CGMs. This includes continuous glucose monitors (CGMs) that integrate with Medtronic insulin pumps to monitor the insulin level during the action.  
• Shift towards Ultra-rapid Acting Insulins: Ultra-rapid acting insulins, including insulin lispro, are gaining popularity in the market. These insulins have a faster onset of action, mimicking the body's natural insulin response more closely. They allow for more flexible dosing and can be beneficial in managing postprandial blood sugar spikes. For instance, in January 2020, Novo Nordisk announced U.S. Food and Drug Administration (FDA) approval for Fiasp which is first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.
• Growing Interest in Closed-loop Systems (Artificial Pancreas): Closed-loop systems, also known as artificial pancreas systems, combine CGM with insulin pump therapy to automate insulin delivery based on glucose levels. This trend is driven by advancements in algorithm technology and offers improved glucose control, reducing the burden of diabetes management for individuals. According to article 'Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions' published by Frontiers magazine in June 2022, There are several hybrid closed loop systems available that work with a variety of pumps and CGMs. CamAPS FX hybrid closed loop uses a DANA or Ypsomed insulin pump and Dexcom CGM. Licenced for aged 1+, Medtronic 670G + Guardian sensors hybrid closed loop uses Medtronic insulin pump and sensors. Licenced for aged 7+, Medtronic 780G + Guardian sensors hybrid closed loop uses Medtronic insulin pump and sensors.